OncoMatch/Clinical Trials/NCT05507411
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Is NCT05507411 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant Chemotherapy and Immunotherapy for esophageal squamous cell carcinoma.
Treatment: Neoadjuvant Chemotherapy · Immunotherapy — To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete remission with watchful waiting strategy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage CT2-4ANANYM0, CT1-3N+M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chest radiotherapy
Received chest radiotherapy ... prior to the start of the trial
Cannot have received: chemotherapy
Received ... chemotherapy ... prior to the start of the trial
Cannot have received: immunotherapy
Received ... immunotherapy ... prior to the start of the trial
Cannot have received: surgery of the esophagus, esophagus and gastric junction, or stomach
Received ... surgery of the esophagus, esophagus and gastric junction, or stomach prior to the start of the trial
Lab requirements
Blood counts
WBC ≥ 2000/μL; Neutrophils ≥ 1500/μL; Platelets ≥ 100x10^3/μL; Hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine ≤1.5 x ULN or calculated creatinine clearance (CrCl) ≥ 50 mL/min (using Cockcroft-Gault formula)
Liver function
AST ≤ 3.0 x ULN; ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN (except for Gilbert syndrome participants, who had total bilirubin < 3.0 x ULN)
Laboratory screening values must meet the following criteria (using CTCAE 4th edition): i) WBC < 2000/μL; ii) Neutrophils < 1500/μL; iii) Platelets < 100x103/μL; iv) Hemoglobin < 9.0 g/dL; v) Serum creatinine <1.5 x ULN or calculated creatinine clearance (CrCl) < 50 mL/min (using Cockcroft-Gault formula); vi) AST >3.0 x ULN; vii) ALT > 3.0 x ULN; viii) Total bilirubin >1.5 x ULN (except for Gilbert syndrome participants, who had total bilirubin < 3.0 x ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify